Table 3 Associations between NAT acetylator genotypes and SSZ-induced ADRs

Total ADRs

7.1%(15/212)

18.5%(10/54)

8.1%(11/136)

10.8%(14/130)

26.3%(10/38)

6.6%(15/228)

P*

0.013

0.45

<0.001

OR*

2.99

5.07

95% CI*

1.26-7.09

2.08-12.37

Drug therapy termination rate due to ADRs

5.2%(11/212)

14.8%(8/54)

5.9%(8/136)

8.5%(11/130)

21.1%(8/38)

4.8%(11/228)

P

0.032#

0.41

0.002#

Dose-related ADR

3.3%(7/212)

16.7%(9/54)

4.4%(6/136)

7.7%(10/130)

23.7%(9/38)

3.1%(7/228)

P*

0.002

0.27

<0.001

OR*

5.17

9.52

95% CI*

1.79-14.92

3.20-28.30

Drug therapy termination rate due to dose-related ADRs

1.4%(3/212)

13.0%(7/54)

2.2%(3/136)

5.4%(7/130)

18.4%(7/38)

1.3%(3/228)

P

0.001#

0.21#

<0.001#

Non-dose-related ADR

3.3%(7/212)

1.8%(1/54)

3.7%(5/136)

2.3%(3/130)

2.6%(1/38)

3.1%(7/228)

P*

0.58

0.51

0.88